Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm clinical trials

Explore recruiting participants with transthyretin amyloid cardiomyopathy attr cm clinical trials.

Recruiting participants with transthyretin amyloid cardiomyopathy attr cm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Open-label extension study of long-term safety and efficacy of NNC6019-0001 in participants with transthyretin amyloid cardiomyopathy (ATTR CM)

Italy, Czechia, Netherlands, France, Spain, Germany +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM).

Portugal, Netherlands, Germany, Spain, Czechia, Italy +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).

Germany, France, Belgium, Italy, Denmark, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Spain, Netherlands, Poland, Italy, Belgium, France +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm trials by city

Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Toronto Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Vancouver Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Montreal Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Calgary Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Edmonton Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Ottawa Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Winnipeg Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Quebec City Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Hamilton Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Kitchener Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in London Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Halifax Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in New York Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Los Angeles Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Chicago Participants With Transthyretin Amyloid Cardiomyopathy Attr Cm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease